In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Fast-SENC segmental intramyocardial strain quantifies subclinical myocardial dysfunction

Session Poster session 1

Speaker Moritz Montenbruck

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance
  • Session type : Poster Session
  • FP Number : P138

Authors : M Montenbruck (Hamburg,DE), S Kelle (Berlin,DE), G Korosoglou (Weinheim,DE), P Wuelfing (Hamburg,DE), S Esch (Hamburg,DE), F Andre (Heidelberg,DE), H Steen (Hamburg,DE)

M Montenbruck1 , S Kelle2 , G Korosoglou3 , P Wuelfing4 , S Esch1 , F Andre5 , H Steen6 , 1Marienkrankenhaus - Hamburg - Germany , 2Deutsches Herzzentrum Berlin - Berlin - Germany , 3GRN-Klinik Weinheim - Weinheim - Germany , 4Mammazentrum am Krankenhaus Jerusalem - Hamburg - Germany , 5University Hospital of Heidelberg - Heidelberg - Germany , 6Marienkrankenhaus, Faculty of University Hospital - Hamburg - Germany ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii83


Left ventricular ejection fraction (LVEF) identifies reduced cardiac function in symptomatic patients.  However, alternative metrics are needed to detect subclinical dysfunction before cardiac remodeling results in systemic damage.  Fast-SENC segmental intramyocardial strain (fSENC) is a unique cardiac magnetic resonance imaging (CMR) modality that measures myocardial contraction in 1 heartbeat per image plane.  This prospective registry compares fSENC and LVEF in patients with varying degrees of progressive dysfunction.


A single center, prospective registry of MRI scans acquired with a 1.5T scanner were evaluated for conventional CMR diagnostics including LVEF, LV-Volumes, LV-Mass, LV-T1/T2 mapping, and Late Gadolinium Enhancement (LGE).  In addition, fSENC scans were acquired and processed with the MyoStrain software to quantify intramyocardial strain.  Three short axis scans (basal, midventricular, & apical) were used to calculate strain in 16 longitudinal segments while three long axis scans (2-chamber, 3-chamber, & 4-chamber) were used to calculate 21 circumferential segments.  fSENC and CMR LVEF were compared based on a modified ACC/AHA Heart Failure Stage ranking that separated stages B and C each into two levels of structural heart disease based on complete CMR evaluation including T1/T2 mapping and LGE analysis.


A total of 792 scans in 619 patients were included in the study.  Patients had an average (± stdev) age of 54 (17) yrs and BMI of 26 (5) kg/m2; 45% had arterial hypertension, 12% diabetes mellitus, 30% valvular heart disease, 27% cancer, 7% atrial fibrillation, and 22% coronary artery disease.

Figure 1 shows the relationship between ACC/AHA Heart Failure stage in the x-axis versus A) the amount of normal myocardium (strain < -17%) and B) CMR LVEF in the y-axis respectively.

fSENC shows a more linear response across all stages of heart failure.  The ability to separate HF stage with a quantitative metric enables detection of subclinical dysfunction before symptoms or clinical change in global CMR measurements such as LVEF, volumes, mass, etc.  Even in patients with normal LVEF, fSENC quantified the progression of structural heart diseases.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are